Randomized Trialhigh evidence
Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.
Lancet (London, England)·September 17, 2026·PMID 42753775
Why it mattersAdolescents with HIV often struggle with daily oral adherence, leading to poorer outcomes. Long-acting injectable therapy may improve virological suppression in this vulnerable group, and this trial provides direct evidence of superiority over standard oral therapy in a sub-Saharan African setting.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled